Acyclovir, Plasma
Use
Therapeutic drug monitoring of acyclovir levels in plasma to assess dosing adequacy; reference ranges include peak (0.40–2.0 mcg/mL) and trough (0.14–1.2 mcg/mL) during chronic oral dosing, and expected acyclovir levels following valacyclovir administration (2.0–4.0 mcg/mL) (peak) ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/75396?utm_source=openai)).
Special Instructions
Not provided.
Limitations
This test was developed and its performance characteristics determined by NMS Labs and has not been cleared or approved by the U.S. Food and Drug Administration ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/75396?utm_source=openai)).
New York Approved
Methodology
Mass Spectrometry (LC‑MS/MS)
Biomarkers
Acyclovir
Analyte
LOINC Codes
- 9416-9 - Acyclovir SerPl-mCnc
Result Turnaround Time
9-11 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Lavender top or pink top (EDTA) tube; plasma must be aliquoted into plastic vial
Collection Instructions
Draw blood in EDTA (lavender or pink top) tube; centrifuge and aliquot 1 mL plasma into plastic vial; send refrigerated.
Storage Instructions
Refrigerated (preferred), ambient acceptable, frozen acceptable
Causes for Rejection
Plasma gel/PST tubes not acceptable.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 30 days |
| Refrigerated | 30 days |
| Frozen | 120 days |